IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best in Class MTA cooperative PRMT5 Inhibitor

Monday, December 9, 2024 1 min read

Key Takeaway: IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best in Class MTA cooperative PRMT5 Inhibitor

Full Press Release Details

IDEAYA Biosciences Announces Development Candidate Nomination of IDE892, a Potential Best in Class MTA cooperative PRMT5 Inhibitor.